REXO2

Across TCGA pan-cancer cohorts, REXO2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated REXO2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher REXO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated REXO2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where REXO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.274	0.978	.001	16	view →
GBM	DFS	Quartile	All	0.215	0.491	<.001	12	view →
LSCC	DFS	Median	III,IV	0.415	0.888	.001	12	view →
PDAC	DFS	Median	IV	0.766	0.234	.026	7	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

REXO2–CCRCC (DFS)

Open the CCRCC breakdown →